Statin treatment following coronary artery stenting and one-year survival
Albert Schömig, MD* ,*,
Julinda Mehilli, MD*,
Heidrun Holle, RN*,
Karin Hösl, RN*,
Dorejd Kastrati*,
J.ürgen Pache, MD ,
Melchior Seyfarth, MD ,
Franz-Josef Neumann, MD ,
Josef Dirschinger, MD and
Adnan Kastrati, MD*
* Deutsches Herzzentrum, Munich, Germany
1. Medizinische Klinik rechts der Isar, Technische Universität, Munich, Germany

View larger version (16K):
[in a new window]
|
Figure 1 Cumulative one-year mortality curves for patients with and without statins.
|
|

View larger version (12K):
[in a new window]
|
Figure 2 Analysis of the influence of statin therapy on one-year mortality according to the study period.
|
|

View larger version (34K):
[in a new window]
|
Figure 3 Analysis of the influence of statin therapy on one-year mortality in various patient subsets. ACE = angiotensin-converting enzyme.
|
|

View larger version (13K):
[in a new window]
|
Figure 4 Analysis of the influence of statin therapy on one-year mortality in four equally sized (quartiles) subgroups of patients defined on the basis of the propensity score. The propensity score indicates the probability for the patient to be given statins on the basis of his/her baseline characteristics.
|
|

View larger version (18K):
[in a new window]
|
Figure 5 Significant independent predictors of the risk of death derived from the Cox proportional hazard model. LVEF = left ventricular ejection fraction.
|
|
|